OGN

SEC source: 0001628280-25-051733 · wk-form4_1762987721.xml · nonDerivative · entry 1

Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,416.703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-26-002406 · wk-form4a_1768599463.xml · nonDerivative · entry 1

Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,174.703

F1 · balance_after: On November 12, 2025, the reporting person filed a Form 4 which inadvertently reported that she acquired (A) 1,242 shares of Organon & Co. (Organon) common stock due to the sale of shares to satisfy a tax liability related to the acquisition of other shares of Organon common stock (code F), where in fact this number of shares should have been reported as a transaction resulting in her disposal (D) of such shares to satisfy the tax liability. As a result, the total amount of securities beneficially owned by the reporting person following such sale transaction on November 7, 2025, is now correctly reported on this Form 4 in column 5 as 17,174.703.

SEC source: 0001628280-25-050186 · wk-form4_1762463515.xml · derivative · entry 3

Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,076

Underlying: Common Stock · 3,037 shares

Expires 2027-11-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the first vesting on November 5, 2025, and the final vesting date being on November 5, 2027.

SEC source: 0001628280-25-050186 · wk-form4_1762463515.xml · nonDerivative · entry 2

Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,948.427

SEC source: 0001628280-25-050186 · wk-form4_1762463515.xml · nonDerivative · entry 1

Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,814.427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001821825-25-000068 · wk-form4_1755029130.xml · derivative · entry 3

Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,519

Underlying: Common Stock · 11,519 shares

Expires 2026-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon & Co. common stock in three equal installments with 11,519 shares having vested on August 11, 2025 and the third and final vesting to occur on August 11, 2026.

SEC source: 0001821825-25-000068 · wk-form4_1755029130.xml · nonDerivative · entry 2

Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,777.355

SEC source: 0001821825-25-000068 · wk-form4_1755029130.xml · nonDerivative · entry 1

Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,899.355

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001821825-25-000063 · wk-form4_1751489156.xml · derivative · entry 1

Sequeira Ramona · CIK 0001811081 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,890.547

Underlying: Common Stock · 21,890.547 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the person's termination of service as a director pursuant to the terms of the Plan.

SEC source: 0001821825-25-000059 · wk-form4_1750111465.xml · derivative · entry 1

Ozuah Philip · CIK 0001859685 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.657

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000049 · wk-form4_1750109097.xml · derivative · entry 1

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.656

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000041 · wk-form4_1750108628.xml · derivative · entry 1

COX CARRIE SMITH · CIK 0001110753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,029.769

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000045 · wk-form4_1750108854.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.653

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000047 · wk-form4_1750108969.xml · derivative · entry 1

Gayle Helene D · CIK 0001487047 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.656

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000043 · wk-form4_1750108745.xml · derivative · entry 1

ESSNER ROBERT · CIK 0001187297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.652

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000055 · wk-form4_1750109646.xml · derivative · entry 1

Sharp Shalini · CIK 0001377202 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,054.148

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000053 · wk-form4_1750109538.xml · derivative · entry 1

Patton Cynthia M · CIK 0001560565 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.653

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000051 · wk-form4_1750109446.xml · derivative · entry 1

Whiteford Grace Puma · CIK 0001706213 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.652

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000057 · wk-form4_1750111308.xml · derivative · entry 1

Leone Deborah R · CIK 0001859703 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.655

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0001821825-25-000037 · wk-form4_1747339741.xml · nonDerivative · entry 1

COX CARRIE SMITH · CIK 0001110753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,469

F1 · price: The price reported is a weighted average price (which was $8.06727998, rounded due to character limitations in the price field). These shares were purchased in multiple transactions at prices ranging from $8.059 to $8.07, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001821825-25-000033 · wk-form4_1746634421.xml · nonDerivative · entry 1

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,973.661

SEC source: 0001821825-25-000031 · wk-form4_1746634336.xml · nonDerivative · entry 1

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,489

SEC source: 0001821825-25-000029 · wk-form4_1746634167.xml · nonDerivative · entry 1

Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,669.46

SEC source: 0001821825-25-000027 · wk-form4_1746554362.xml · nonDerivative · entry 1

WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,484

SEC source: 0001821825-25-000025 · wk-form4_1746554281.xml · nonDerivative · entry 1

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,731.157

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.765 to $8.850, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 14

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,294 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F8 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

F8 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 13

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F7 · derivative.exercise_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

F7 · derivative.expiration_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 12

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,200

Underlying: Common Stock · 6,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.

F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 11

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,514

Underlying: Common Stock · 7,757 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 10

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,937

Underlying: Common Stock · 36,937 shares

Expires not disclosed

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.

F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 9

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,518

Underlying: Common Stock · 181,518 shares

Expires not disclosed

F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.

F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 8

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,444

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 7

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,668

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 6

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,374

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 5

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 4

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,140

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 3

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,907

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 2

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,707

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

SEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 1

Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,917

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 10

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,294 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F6 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

F6 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 9

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,504

Underlying: Common Stock · 8,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F5 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.

F5 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 8

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,276

Underlying: Common Stock · 10,638 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F4 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

F4 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 7

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,295

Underlying: Common Stock · 40,295 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F3 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.

F3 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 6

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,740

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 5

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 4

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,917

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 3

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 2

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,327

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

SEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 1

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,971

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · derivative · entry 5

Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,730

Underlying: Common Stock · 8,865 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.